Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.
Intellia’s CRISPR Gene Editing Therapy NTLA-2002 Appears to Eliminate Hereditary Angioedema Attacks in Some Patients Following One-Time Treatment
Participants in the trial received either a single dose of 25 mg of NTLA-2002, a single dose of 50 mg of NTLA-2002, or a placebo.
CGTLive®’s Weekly Rewind – October 25, 2024
Review top news and interview highlights from the week ending October 25, 2024.
Around the Helix: Cell and Gene Therapy Company Updates – October 23, 2024
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Payer Challenges for Patient Access to Autologous Cell and Gene Therapies
Autologous cell and gene therapies show promise but face barriers such as high costs, limited access, and payer concerns over long-term effectiveness.
CGTLive®’s Weekly Rewind – October 18, 2024
Review top news and interview highlights from the week ending October 18, 2024.
Around the Helix: Cell and Gene Therapy Company Updates – October 16, 2024